To evaluate the Safety and efficacy of Unani formulation in the treatment of Palpitatio
Phase 2
- Conditions
- Health Condition 1: null- Khafaqan (Palpitation)Health Condition 2: R002- Palpitations
- Registration Number
- CTRI/2015/02/005525
- Lead Sponsor
- Central Council for Research in Unani MedicineCCRUM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
•Patients of either sex in the age group of 18-60
•Patients of Palpitation (heart rate: < 60 or >100 bpm) with and without any of the following symptoms/ signs:
ï?§Ghabrahat
ï?§Feeling of Missed Beat
ï?§Discomfort in Chest
ï?§Sweating
ï?§Dizziness
Exclusion Criteria
•History of any heart diseases
•History of hepatic, renal disorders, diabetes mellitus, hypertension, anaemia, COPD
•History of thyroid dysfunction
•History of hypersensitivity to any ingredient of the study drug.
•Participants with history of long term use of any other drugs such as anti-epileptic, anti-arrhythmic and anti-psychotic drugs etc.
•History of Addiction (smoking, alcohol, drugs)
•Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in signs and symptomsTimepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method Hematological and biochemical assessments for safetyTimepoint: 4 weeks